• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SEOM 临床指南:2013 年早期乳腺癌的系统治疗

SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.

机构信息

Medical Oncology Department, Hospital Dr. Josep Trueta, Institut Català d'Oncologia (ICO), Girona, Spain.

出版信息

Clin Transl Oncol. 2013 Dec;15(12):1011-7. doi: 10.1007/s12094-013-1084-3. Epub 2013 Aug 27.

DOI:10.1007/s12094-013-1084-3
PMID:23979909
Abstract

The purpose of this article is to update our previous work on the treatment and follow-up in early breast cancer. In this new version we have classified a treatment by immunohistochemistry subtypes of breast cancer. Latest advances in the management of this disease have been compiled, either in the adjuvant and neoadjuvant setting or chemotherapy and hormonal treatment. This review is presented in an easy way for oncologist, fellows and for other specialties.

摘要

本文旨在更新我们之前关于早期乳腺癌的治疗和随访的工作。在这个新版本中,我们根据乳腺癌的免疫组织化学亚型对治疗进行了分类。我们汇编了这种疾病在辅助和新辅助治疗或化疗和激素治疗方面的最新进展。这篇综述以易于肿瘤学家、研究员和其他专业人员理解的方式呈现。

相似文献

1
SEOM clinical guidelines for the systemic treatment of early breast cancer 2013.SEOM 临床指南:2013 年早期乳腺癌的系统治疗
Clin Transl Oncol. 2013 Dec;15(12):1011-7. doi: 10.1007/s12094-013-1084-3. Epub 2013 Aug 27.
2
[The AIOM (Italian Association of Medical Oncology) practice guidelines for breast neoplasms].
Tumori. 2004 Mar-Apr;90(2):1-8. doi: 10.1177/030089160409000229.
3
SEOM clinical guidelines for the management of metastatic breast cancer 2013.SEOM 临床指南:2013 年转移性乳腺癌的管理
Clin Transl Oncol. 2013 Dec;15(12):1004-10. doi: 10.1007/s12094-013-1095-0. Epub 2013 Oct 23.
4
SEOM clinical guidelines for the treatment of early breast cancer.SEOM 临床指南:早期乳腺癌的治疗。
Clin Transl Oncol. 2010 Nov;12(11):711-8. doi: 10.1007/s12094-010-0584-7.
5
Adjuvant treatment in node-negative, postmenopausal breast cancer.绝经后淋巴结阴性乳腺癌的辅助治疗
Cancer Invest. 2001;19(7):706-22. doi: 10.1081/cnv-100106146.
6
[Neoadjuvant systemic therapy in breast cancer].[乳腺癌的新辅助全身治疗]
Orv Hetil. 2009 Jan 11;150(2):65-71. doi: 10.1556/OH.2009.28536.
7
Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.在新辅助化疗与辅助化疗内分泌治疗的随机试验中,新辅助化疗后cerbB2表达对患者的预后相关性。
Breast Cancer Res Treat. 2000 Jan;59(2):171-5. doi: 10.1023/a:1006394317282.
8
[Early-stage breast cancer - strategies for adjuvant systemic therapy].[早期乳腺癌——辅助性全身治疗策略]
Handchir Mikrochir Plast Chir. 2008 Aug;40(4):230-8. doi: 10.1055/s-2008-1038926. Epub 2008 Aug 20.
9
[Systemic pharmacotherapy in breast cancer].[乳腺癌的全身药物治疗]
Orv Hetil. 2004 Jan 25;145(4):187-92.
10
Neoadjuvant chemotherapy for locally advanced breast cancer.局部晚期乳腺癌的新辅助化疗
Semin Radiat Oncol. 2009 Oct;19(4):222-8. doi: 10.1016/j.semradonc.2009.05.001.

引用本文的文献

1
Association between breast cancer chemotherapy, oral health and chronic dental infections: a pilot study.乳腺癌化疗与口腔健康和慢性牙科感染的相关性:一项初步研究。
Odontology. 2019 Jul;107(3):401-408. doi: 10.1007/s10266-019-00411-z. Epub 2019 Jan 21.
2
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.乳腺癌化疗所致心脏毒性的评估与管理:一项德尔菲研究
Clin Transl Oncol. 2017 Jan;19(1):91-104. doi: 10.1007/s12094-016-1508-y. Epub 2016 Apr 21.
3
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.

本文引用的文献

1
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.雌激素受体阳性乳腺癌诊断后继续辅助他莫昔芬治疗 10 年与 5 年后停药的长期疗效:ATLAS,一项随机试验。
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
2
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.不同内在型乳腺癌亚型新辅助化疗后病理完全缓解对预后的定义和影响。
J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.
3
意大利肿瘤科室的乳腺癌“个性化随访”:一项基于网络的调查。
PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.
4
SEOM guidelines 2013: a response to the needs of Spanish oncologists.《2013年SEOM指南:对西班牙肿瘤学家需求的回应》
Clin Transl Oncol. 2013 Dec;15(12):975-6. doi: 10.1007/s12094-013-1097-y. Epub 2013 Aug 8.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
拉帕替尼联合曲妥珠单抗治疗人表皮生长因子受体 2 阳性早期乳腺癌(NeoALTTO):一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17.
4
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性(NeoSphere):一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
5
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.不同化疗方案治疗早期乳腺癌的比较:123 项随机试验 10 万名女性长期结局的荟萃分析。
Lancet. 2012 Feb 4;379(9814):432-44. doi: 10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5.
6
Adjuvant trastuzumab in HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌。
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
7
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.曲妥珠单抗联合辅助化疗治疗可手术的人表皮生长因子受体 2 阳性乳腺癌的 4 年随访:NCCTG N9831 和 NSABP B-31 数据的联合分析。
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
8
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.亚型策略——应对乳腺癌的多样性:2011 年圣加仑国际乳腺癌专家共识会议关于早期乳腺癌初始治疗的要点。
Ann Oncol. 2011 Aug;22(8):1736-47. doi: 10.1093/annonc/mdr304. Epub 2011 Jun 27.
9
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.曲妥珠单抗辅助化疗后治疗 1 年用于人表皮生长因子受体 2 阳性早期乳腺癌患者:一项随机对照试验的 4 年随访。
Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.
10
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.将贝伐珠单抗、依维莫司和拉帕替尼纳入原发性乳腺癌新辅助化疗方案。GeparQuinto 试验的安全性结果。
Ann Oncol. 2011 Feb;22(2):301-6. doi: 10.1093/annonc/mdq350. Epub 2010 Jul 12.